Although no definitive conclusions can be drawn, this current study is among the first in-human studies to demonstrate that IV-administered pelareorep was present in the post-treatment KRAS-activated pancreatic cancer, indicating the ability of reovirus to penetrate the peritumoral desmoplastic stroma, which is a hallmark of pancreatic cancer and a known barricade against chemotherapy. Here, KRAS is linked to pancreatic neoplasm.